RH5.1/Matrix-M Malaria Vaccine Shows Promise as Blood-Stage Defense
• A Phase IIb trial of the RH5.1/Matrix-M vaccine shows 55% efficacy in preventing clinical malaria over six months in young children.
• The vaccine also demonstrated over 80% efficacy against high levels of malaria parasites, suggesting potential in preventing severe cases.
• RH5.1/Matrix-M targets the blood-stage of malaria, complementing existing vaccines that target the liver-stage of the parasite.
• The RH5.1/Matrix-M vaccine was well-tolerated, with mild adverse events, positioning it as a potential second line of defense against malaria.
© Copyright 2025. All Rights Reserved by MedPath